# Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

> **NCT03793712** · PHASE2 · TERMINATED · sponsor: **H. Lundbeck A/S** · enrollment: 168 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lu AF11167 (1-2 mg/day)
- **DRUG:** Lu AF11167 (3-4 mg/day)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03793712
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-27
- **Primary completion:** 2020-08-20
- **Final completion:** 2020-09-03
- **Target enrollment:** 168 (ACTUAL)
- **Why stopped:** Lack of efficacy based on interim analysis
- **Last updated:** 2020-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03793712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03793712, "Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03793712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*